Xenetic End Period Cash Flow vs Net Income Analysis
| XBIO Stock | USD 4.20 0.09 2.19% |
Xenetic Biosciences financial indicator trend analysis is more than just analyzing Xenetic Biosciences current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xenetic Biosciences is a good investment. Please check the relationship between Xenetic Biosciences End Period Cash Flow and its Net Income accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.
End Period Cash Flow vs Net Income
End Period Cash Flow vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xenetic Biosciences End Period Cash Flow account and Net Income. At this time, the significance of the direction appears to have weak relationship.
The correlation between Xenetic Biosciences' End Period Cash Flow and Net Income is 0.3. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Net Income in the same time period over historical financial statements of Xenetic Biosciences, assuming nothing else is changed. The correlation between historical values of Xenetic Biosciences' End Period Cash Flow and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Xenetic Biosciences are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of End Period Cash Flow i.e., Xenetic Biosciences' End Period Cash Flow and Net Income go up and down completely randomly.
Correlation Coefficient | 0.3 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
End Period Cash Flow
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Xenetic Biosciences financial statement analysis. It represents the amount of money remaining after all of Xenetic Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Xenetic Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xenetic Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.At this time, Xenetic Biosciences' Selling General Administrative is very stable compared to the past year. As of the 29th of November 2024, Enterprise Value Over EBITDA is likely to grow to 0.86, while Issuance Of Capital Stock is likely to drop 0.00.
Xenetic Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Xenetic Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Xenetic Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 21.5M | 13.2M | 19.8M | 14.7M | 10.6M | 18.0M | |
| Other Current Liab | 484.0K | 609.5K | 1.0M | 785.8K | 568.8K | 997.5K | |
| Total Current Liabilities | 1.4M | 936.9K | 1.4M | 1.1M | 809.6K | 1.6M | |
| Total Stockholder Equity | 17.2M | 12.2M | 18.4M | 13.6M | 9.8M | 13.7M | |
| Net Debt | (10.3M) | (11.5M) | (18.2M) | (13.1M) | (9.0M) | (9.4M) | |
| Retained Earnings | (166.0M) | (176.9M) | (182.5M) | (189.1M) | (193.2M) | (202.9M) | |
| Accounts Payable | 931.1K | 327.4K | 362.5K | 287.4K | 240.8K | 228.8K | |
| Cash | 10.4M | 11.5M | 18.2M | 13.1M | 9.0M | 7.7M | |
| Non Current Assets Total | 10.5M | 810.0K | 1.1M | 1.1M | 1.0M | 967.4K | |
| Cash And Short Term Investments | 10.4M | 11.5M | 18.2M | 13.1M | 9.0M | 7.7M | |
| Common Stock Total Equity | 9.0K | 9.7K | 6.1K | 8.8K | 7.9K | 7.5K | |
| Liabilities And Stockholders Equity | 21.5M | 13.2M | 19.8M | 14.7M | 10.6M | 18.0M | |
| Total Liab | 4.3M | 964.0K | 1.4M | 1.1M | 809.6K | 769.1K | |
| Total Current Assets | 11.1M | 12.4M | 18.7M | 13.7M | 9.6M | 8.9M | |
| Common Stock | 6.1K | 8.8K | 13.5K | 15.2K | 1.5K | 1.5K | |
| Non Currrent Assets Other | 1.2M | 782.9K | 1.1M | 1.1M | 1.0M | 697.2K | |
| Common Stock Shares Outstanding | 285.2K | 639.2K | 1.0M | 1.4M | 1.5M | 1.6M | |
| Other Current Assets | 722.1K | 225K | 252.4K | 556.1K | 603.8K | 617.8K | |
| Other Stockholder Equity | 183.0M | 188.9M | 200.7M | 202.5M | 202.8M | 162.6M | |
| Net Tangible Assets | (2.6M) | 8.0M | 12.2M | 18.4M | 21.2M | 22.2M | |
| Retained Earnings Total Equity | (145.9M) | (153.2M) | (166.0M) | (176.9M) | (159.2M) | (167.2M) | |
| Capital Surpluse | 165.2M | 168.2M | 188.2M | 194.1M | 223.3M | 157.1M | |
| Property Plant Equipment | 27.8K | 5.0K | 757.0 | 27.0K | 24.3K | 43.7K | |
| Other Assets | 705.7K | 1.2M | 810.0K | 1.1M | 1.3M | 679.4K | |
| Net Invested Capital | 17.2M | 12.2M | 18.4M | 13.6M | 9.8M | 10.9M | |
| Net Working Capital | 9.7M | 11.4M | 17.3M | 12.6M | 8.8M | 9.9M | |
| Capital Stock | 8.9K | 11.5K | 16.2K | 18.0K | 3.3K | 3.2K |
Pair Trading with Xenetic Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.
The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.